Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Combined with Chemotherapy for Advanced Biliary Tract Cancer
NCT03796429Phase 2Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2018
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in biliary tract cancer (BTC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Progression-Free Survival at 36 months and Overall Survival at 36 months. Started Dec 2018; status: completed.
02
Drugs
toripalimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03796429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796429.